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Short Communication
Partial characterization of a membrane antigen which
exhibits specificity for cells of patients with acute
myelogenous leukaemia
R. Shipman, A. Malcolm & J.G. Levy
Department ofMicrobiology, University ofBritish Columbia, Vancouver, B.C. Canada, V6T IW5.
A number of investigators have reported finding
tumour-associated antigens (TAA) on cells of
patients with myeloblastic leukaemia. These
antigens have been described as being a
glycoprotein of 75-80K dalton mol. wt (Baker et
al., unpublished data), a glycoprotein of 400K
dalton mol. wt (Taub et al., 1978), or cell stage
dependent proteins of 86K dalton mol. wt,
respectively (Mulder et al., 1981).
In this laboratory, we have identified what
appears to be a TAA on human acute myelogenous
leukaemia (AML) cells. This material, when isolated
on native polyacrylamide gels and used to raise a
conventional antiserum in rabbits, demonstrated
complete specificity for AML cell membrane
extracts in the ELISA (Malcolm et al., 1982). It did
not react with equivalent preparations of either
normal peripheral blood leucocytes (PBL) or cells of
patients with lymphoproliferative disorders. Further
studies using this antiserum in FACS IV analyses
established that the antigen with which it reacted
was on the surface of bone marrow AML cells, but
did not react with surface antigens of normal bone
marrow cells or those of patients with other
disorders (Malcolm et al., 1982). More recently
(Malcolm et al., 1983), in a more extensive study,
we have confirmed the apparent specificity of this
antiserum with both PBL and bone marrow cells
from a larger patient group. The present report
constitutes a preliminary characterization of this
TAA.
In the original procedures used for the
preparation of the antigen, extracts of cell
membranes from AML patients were passed
initially over an immunoadsorbent column
containing antiserum raised in rabbits to a pool of
normal PBL membrane extracts (anti-normal
human). The "fall-through" material was then run
on preparative non-reducing polyacrylamide gels
and the unique bands were cut out and eluted.
These preparations were then used to immunize
rabbits. In the original study, 3 unique bands of
protein were isolated (Malcolm et al., 1982). It was
subsequently found that the rabbit antisera, raised
to each of these bands, were totally cross-reactive,
indicating that the individual bands probably
represented aggregated forms of the same antigen.
This was further verified when materials were run
on reducing gels, and it was found that only one
band (mol. wt -68K daltons) was observed under
these conditions (data not shown).
In order to determine whether the same protein
band was present in extracts of cells from a number
of individual patients with myelogenous leukaemia,
or if it was detectable in extracts of cells from
patients with lymphoproliferative disorders,
individual extracts were prepared as described
previously (Malcolm et al., 1982), absorbed over the
"anti-normal human" immunoadsorbent and run on
SDS-PAGE according to previously described
procedures (Laemmli, 1970; Gold et al., 1976).
Preparations previously equilibrated with SDS and
2-ME, were applied to 7.5% polyacrylamide gels
and electrophoresed at 70V for 5-6h. The results
(Figure 1) indicate that the 68K dalton component
is present in all cell extracts from AML patients but
is not detectable in extracts from other patient
groups. These findings were not surprising in the
light of previous observations that antisera raised
against gel-purified AML proteins reacted only with
either extracts or cells from patients with
myelogenous leukaemias (Malcolm et al., 1982,
1983).
Preparative reducing gels of absorbed AML cell
extracts were run, and sufficient antigen eluted and
concentrated from a number of individual patient
samples so that they could be tested in 2-
dimensional gels to assess their purity, using the
procedures of O'Farrell (1975). Gels were developed
using the silver stain (Wray et al., 1981). The results
(Figure 2) show that the AML antigen is composed
of a major protein component of -68K daltons
mol. wt with a pl between 7.1 and 7.2. The "tailing"
seen is possibly due to differential glycosylation of
the material. It should be noted that the bands of
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Figure 1 SDS-PAGE of a number of absorbed
membrane extracts from a variety of sources. Lanes a-
d; absorbed membrane extracts of 4 individual AML
cell samples. Lane e; absorbed membrane extract of an
AMML (acute monomyelocytic leukaemia) cell sample.
Lane f; low mol. wt standards. Lanes g-i; absorbed
membrane extracts of a pre-CLL (chronic lymphocytic
leukaemia), an ALL (acute lymphocytic leukaemia)
bone marrow and normal human buffy coat cell
samples, respectively. Gel was silver stained according
to the method of Wray et al. (1981).
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Figure 2 2D gel of AML band 1. Lane a; low mol. wt standards. Lane b; Five pg of AML antigenic material
was loaded onto an IEF tube gel containing 2% LKB Ampholines. The sample was focussed at 400V for 24h,
after which it was extruded and equilibrated with SDS-PAGE running buffer. The IEF tube gel was placed
onto a 7.5% SDS-PA gel and electrophoresed at 70V for 5h. The finished gel was then silver stained
according to the method of Wray et al. (1981). The lines of positively staining material seen below the protein
are artifacts of the staining procedure and do not represent protein material.
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material (between 50-60K daltons mol. wt) visible
on the gel represent artifacts of the silver staining
procedure. They appear consistently in all gels, even
those which are run with no protein samples. When
1251-labelled AML antigen was run on 2D gels,
these bands are not seen; however, some breakdown
of the antigen itself was seen, presumably due to
oxidation (Figure 3).
We were interested to establish whether the
purified AML antigen was capable of blocking the
ability of the anti-AML-antiserum described earlier
(Malcolm et al., 1982) to bind the HL-60 human
cell line (derived from a promyelocytic leukaemia,
and obtained from Dr. R.C. Gallo, N.C.I., Bethesda,
Md.). An inhibition assay was performed, in which
either normal human membrane antigens or the
AML antigen (both at concentrations of40pgml-')
were preincubated with either normal rabbit serum
(NRS), rabbit antiserum to normal human PBL
membrane antigens, or to the purified AML
antigen. Antisera were then reacted with HL-60
cells for subsequent FACS IV analysis as described
previously (Malcolm et al., 1982). The results (Table
I) show clearly that the AML antigen successfully
blocks the reaction of the specific anti-AML
antiserum with HL-60 but has no effect on the
pH 6.4
Table I Results of FACS IV analysis of HL-60 cells with
sera (1: 10 dilution) which had been incubated with the
AML antigen, absorbed normal cell membrane antigen or
PBS prior to labeling and analysis. A total of 25,000 cells
was analysed in each case
No. ofcells
Serum used Inhibitor fluorescing
NRS 3,787
NRS normal membrane 4,127
NRS AML antigen 3,485
Anti-normal human 22,392
Anti-normal human normal membrane 3,560
Anti-normal human AML antigen 20,927
Anti-AML-antigen 13,175
Anti-AML-antigen normal membrane 13,370
Anti-AML-antigen AML antigen 4,547
positive control (anti-normal human). Conversely,
normal membrane extracts successfully block the
reaction of the anti-normal antiserum but do not
interfere with the reaction of the anti-AML-
antiserum with HL-60.
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Figure 3 2D gel of 125I-labelled AML band 1. Two Mg of radiolabelled AML antigenic material (Greenwood
et al., 1963) was focussed, electrophoresed and stained, as described in Figure 2. Following drying the gel was
autoradiographed for 18h at -70°C using Kodak X-Omat R film and Dupont Cronex Lightning-Plus X-ray
intensifying screens. Mol. wt standards as indicated.
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In conclusion, our preliminary characterization of
an antigen, which appears to be exclusively present
on or in cells of patients with myloproliferative
disorders, has shown the following. The same
antigen as defined by a band seen on SDS-PAGE
of absorbed membrane extracts, appears to be
present in all AML cell extracts tested but was not
found in equivalent preparations from cells from
normal individuals or patients with
lymphoproliferative disorders. This putative AML
antigen, when eluted from preparative SDS-gels was
found to be homogeneous in 2D gels and has been
assigned a mol. wt of 68K daltons, and a pl of
between 7.1 and 7.2. Finally, we have shown that
this antigen can inhibit the reaction of a rabbit
antiserum (prepared earlier in this laboratory) to
bind to the surface of the HL-60 cell line,
establishing that the AML antigen characterized
here represents a surface marker on this cell line,
and probably on cells of AML patients.
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